UMIP-292 – Recombinant AAV viral vectors capable of glycoengineering in vivo

Problem: The constant domain of human IgG contains a single N-linked oligosaccharide at asparagine-297. The absence of fucose on thecarbohydrate at this site can have a dramatic impact onantibody-dependent cellular cytotoxicity (ADCC) activity. Non-fucosylatedantibody has been shown to increase ADCC activity from 10-100times that of the fucosylated version. Thesefindings have generated much interest in thetherapeutic antibody field. Glycoengineeredversions of several therapeutic antibodies for cancer are already in clinicaltrials. Current techniques ofglycoengineering do not apply to antibody production methods using viral vectors such as adeno-associated viral vectors. Technology: Researchersat the University of Miami have developed a method ofglycoengineering a recombinant adeno-associated viral (AAV)-vector in vivo. In particular, the present disclosure relates to a novelcomposition of matter and method of manufacture forrecombinant AAV viral vectors capable of being glycoengineered in vivo. There is currently great interest in using AAV todeliver antibodies with potent neutralizing activity against a broad range ofHIV isolates. The increased potency (ADCC activity) of antibodies againstchronic viral diseases, such as HIV, delivered by AAV vector using thistechnology holds great promise for being able to greatly impact the viralreservoir even when viral replication is suppressed. Peter Gutenberg pxg372@miami.edu 305-243-4604